Genetic Signatures has abandoned its proposed all-scrip merger with Microba Life Sciences after the board decided against providing unsecured debt funding to cover Microba's working capital needs during implementation, Business News Australia reported. The September announcement had attributed an equity value of $15.9 million to Genetic Signatures and $35.1 million to Microba.
Microba disclosed to the market that finishing the transaction required more capital than it had, one day before Genetic Signatures walked away. The Genetic Signatures board cited associated risks and potential regulatory requirements in declining to extend the loan. At 30 September, Microba held $3.87 million in cash after a net operating outflow of $3.80 million for the quarter, leaving an estimated 1.02 quarters of runway at that spending pace.
The two companies had identified potential annualised gross cost synergies of at least $2.5 million to $3 million from the combination. Revised terms reached on 21 October increased the existing Genetic Signatures shareholders' slice to 40%, compared with roughly 33% under the September proposal, but no binding documentation had been executed.
Microba locked in commitments on 20 October for a $2.025 million placement split across two tranches at 4c per share, representing a 9.1% discount to the prior closing price of 4.4c, with Sonic Healthcare, Perennial Partners, Thorney and Microba directors participating. The $1 million second tranche was conditional on approval from both sets of shareholders for the merger.
Genetic Signatures said its board had been in talks with Microba about the unsecured debt but ultimately decided against it, and acknowledged that both companies had invested substantial time and effort in pursuing the merger. Microba described the collapse as a poor result given the extended period of work, and said it had actively sought alternative funding.
Cancer diagnostics company BCAL Diagnostics, which holds 18.46% of Genetic Signatures, lodged an application with the Takeovers Panel on 13 November. Genetic Signatures will pull the relevant securities-issuance resolution before its AGM on 30 November.
Microba has brought its annualised cash operating costs down by about $5 million, exceeding a 20% reduction relative to the prior full year, with an additional annualised saving of about $3 million targeted. Core testing revenue reached $2.57 million in the September quarter, a 31% increase over the same period a year earlier. The company disclosed in October that it intended to run an advisory process aimed at a possible sale of its UK-based Invivo Supplements unit.
Microba shareholders face uncertainty over the company's funding position, as it remains in voluntary suspension while exploring options for capital and assessing its cashflow. The second tranche of its $2.025 million placement is now in doubt as it was conditional on shareholder approval from both companies for the merger, with Microba's cash runway estimated at just over one quarter at the most recent burn rate.
Reporting: Business News Australia
Background: Business News Australia, The Conversation
Written by Pick & Scroll News from the reporting and documents linked above.

